This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Glaxosmithkline Intellectual Property (No.2) Limited, Glaxosmithkline Intellectual Property Development Limited. Active years: 2016-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 95 
1 out of 242 
Years Active: 2016-2022
Title: The Innovative Contributions of Dai-Shi Su
Introduction
Dai-Shi Su is a notable inventor based in Collegeville, PA, who has made significant contributions to the field of pharmaceutical sciences. With a total of three patents to his name, his work focuses on developing novel compounds that address various metabolic and psychiatric disorders.
Latest Patents
One of Dai-Shi Su's latest patents is related to Ghrelin O-acyltransferase inhibitors. This invention involves novel compounds that inhibit ghrelin O-acyltransferase (GOAT) and includes pharmaceutical compositions for treating metabolic disorders such as Prader-Willi syndrome, metabolic syndrome, and type II diabetes mellitus. Another significant patent is for Enhancer of Zeste Homolog 2 inhibitors, which are also novel compounds aimed at inhibiting EZH2 and include pharmaceutical compositions for therapeutic use.
Career Highlights
Dai-Shi Su has worked with prominent companies in the pharmaceutical industry, including GlaxoSmithKline Intellectual Property Limited and GlaxoSmithKline Intellectual Property Development Limited. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.
Collaborations
Dai-Shi Su has collaborated with notable colleagues such as Charles William Blackledge, Jr. and Joelle Lorraine Burgess, enhancing the scope and impact of his research and inventions.
Conclusion
Dai-Shi Su's innovative work in developing inhibitors for metabolic and psychiatric disorders showcases his commitment to advancing pharmaceutical science. His contributions are significant in addressing complex health issues and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile